Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2026)

Xeris Biopharma Holdings' Cost of Revenue history runs 7 years deep, the most recent figure standing at $10.6 million for Q1 2026.

• Quarterly Cost of Revenue rose 21.15% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.4 million (up 12.19% YoY) and the FY2025 annual result came in at $42.6 million, up 15.58% from the prior year.
• Cost of Revenue was $10.6 million for Q1 2026 at Xeris Biopharma Holdings, down from $10.9 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $13.6 million in Q3 2024 and bottomed at $4.8 million in Q2 2022.
• A 5-year average of $8.3 million and a median of $7.8 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 243.54% — and 2025, when it dropped 19.11%.
• Xeris Biopharma Holdings' Cost of Revenue stood at $6.3 million in 2022, then grew by 20.33% to $7.6 million in 2023, then climbed by 25.2% to $9.5 million in 2024, then advanced by 15.5% to $10.9 million in 2025, then decreased by 3.41% to $10.6 million in 2026.
• Business Quant data shows XERS's Cost of Revenue at $10.6 million in Q1 2026, $10.9 million in Q4 2025, and $11.0 million in Q3 2025.